You are here: Industry Insights > Ad26.COV2.S

News List

Press Release Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses FirstWordPharma
December 06, 2021
Preliminary Phase 2 study and a sub-study demonstrate value of mix-and-match approach; Johnson & Johnson booster increased neutralizing and binding antibodies, similar to boosting with BNT162b2, and showed strong increase in T-cell responses.
FDA finds J&J’s single-dose Covid-19 vaccine safe and effective in trials pharmaceutical-technology
February 26, 2021
The US Food and Drug Administration (FDA) said that Johnson & Johnson’s single-shot Covid-19 vaccine, Ad26.COV2.S is safe and effective, according to the data submitted from its ongoing Phase III trials.
EMA initiates rolling review of Janssen’s Covid-19 vaccine candidate pharmaceutical-technology
December 03, 2020
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a rolling review of Janssen and Cilag International’s Covid-19 vaccine candidate, Ad26.COV2.S.
J&J COVID-19 vaccine candidate yields strong immune response in early trial expresspharma
September 27, 2020
Immune response results were available from only 15 people over 65 years old, limiting the interpretation.
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines europeanpharmaceuticalreview
September 03, 2020
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
J&J Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine americanpharmaceuticalreview
August 07, 2020
Johnson & Johnson announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational ...
J&J signs pact with US for 100 million doses of COVID-19 vaccine expresspharma
August 07, 2020
The US government is committing over $1 billion for this agreement.
J&J Wins $1B U.S. Contract for SARS-CoV-2 Vax contractpharma
August 06, 2020
To provide large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine.
J&J begins first trial of Covid-19 vaccine after positive preclinical data pharmaceutical-technology
August 03, 2020
Johnson & Johnson (J&J) has started a Phase I/IIa clinical trial of its Covid-19 vaccine candidate, Ad26.COV2.S, in healthy volunteers across the US and Belgium.
J&J’s Lead COVID-19 Vax Candidate Elicits Immune Response contractpharma
July 31, 2020
Preclinical data shows adenovirus serotype 26 vector-based vaccine elicited a robust immune response as demonstrated by neutralizing antibodies.